Saroglitazar

Zydus Lifesciences plans to acquire commercial assets via M&A or licensing for a specialty portfolio, including potential US launch of liver therapy saroglitazar. The company aims to diversify into medical devices, expand diagnostics and nutrition businesses, and build a specialty play in the US, particularly in orphan and rare diseases. Zydus also targets Europe for M&A, focusing on profitable growth and innovation in unmet medical needs, including orphan and rare diseases. The company is bullish on biologics and globalizing its biosimilars portfolio, with a new facility set to commission in 2025. Zydus received WHO approval for a typhoid conjugate vaccine and expects significant supply orders from UNICEF. The company remains committed to the US market despite potential pricing pressures and political changes.